[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Jevtić, 2021 - Google Patents

Identification of NUP98-NSD1 Interactors and Their Implication in Acute Myeloid Leukemia

Jevtić, 2021

Document ID
5480114690383005581
Author
Jevtić
Publication year
Publication venue
PQDT-Global

External Links

Snippet

NUP98 rearrangements present the second largest group of gene fusions in acute myeloid leukemia (AML) with 32 distinct NUP98 fusion partner genes identified. Two decades after their discovery and characterization, these translocations define a biologically distinct group …
Continue reading at search.proquest.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Volk et al. A CHAF1B-dependent molecular switch in hematopoiesis and leukemia pathogenesis
Aranda-Orgilles et al. MED12 regulates HSC-specific enhancers independently of mediator kinase activity to control hematopoiesis
Tanaka et al. Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies
Kong et al. MEF2C and EBF1 co-regulate B cell-specific transcription
Bera et al. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
Man et al. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia
Lenaerts et al. EBF1 primes B-lymphoid enhancers and limits the myeloid bias in murine multipotent progenitors
Chang et al. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response
Kanki et al. Bivalent-histone-marked immediate-early gene regulation is vital for VEGF-responsive angiogenesis
Liu et al. The transcription factor Zfp90 regulates the self-renewal and differentiation of hematopoietic stem cells
Wang et al. USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potential
Jevtić Identification of NUP98-NSD1 Interactors and Their Implication in Acute Myeloid Leukemia
Manukjan et al. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro
Ma et al. Growth arrest‐specific protein 2 (GAS2) interacts with CXCR4 to promote T‐cell leukemogenesis partially via c‐MYC
Mrouj et al. Ki-67 promotes sequential stages of tumourigenesis by enabling cellular plasticity
Szybinski Role of unphosphorylated STAT5 in maintenance of Acute Myeloid Leukemia cells
Binhassan PHF6 as a novel interactor of the transcriptional co-regulator LMO2 in T-Cell acute lymphoblastic leukaemia (T-ALL) and myeloid differentiation
EP4079855A1 (en) Compound and method for the prophylaxis and treatment of leukemia
Nakata et al. JMJD3 mediated senescence is required to overcome stress induced hematopoietic defects.
Serio The Polymerase Associated Factor Complex-Protein Arginine Methyltransferase Axis: A Mechanism of Acute Leukemia
Chaikovsky Using CDK4/6 Inhibitors to Identify Novel Regulators of the RB Pathway
Rodríguez Díaz From cancer stem cells to brain tumour formation: the role of HEATR1 and ribosome biogenesis
Kugler et al. A single amino acid at PNT domain of ERG mediates its leukemogenic activity through interaction with the NCoR-HDAC3 co-repressor complex
Dastpak et al. Chemokine Receptor 1 and its associated immune pathway are downregulated in SF3B1MT blood and non-blood cancers
Khateb et al. RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors